Quarterly ResultOct 13, 2026, 08:21 AM
Johnson & Johnson Q3 Sales $25.4B (+5.9%); Raises 2026 Guidance
AI Summary
Johnson & Johnson reported Q3 2026 results with sales up 5.9% to $25.4 billion, driven by operational growth in both Innovative Medicine and MedTech segments. However, adjusted EPS decreased by 7.5% to $2.59 due to one-time charges. The company raised its full-year 2026 guidance, expecting reported sales between $101.0B - $101.4B. Key developments include the acquisition of Firefly Bio, Inc., a collaboration with Sail Biomedicines, and significant regulatory approvals for new treatments and devices.
Key Highlights
- Johnson & Johnson reported Q3 2026 sales of $25.4 billion, a 5.9% increase YoY.
- Adjusted EPS for Q3 2026 was $2.59, a 7.5% decrease YoY.
- Full-year 2026 guidance raised; estimated reported sales of $101.2 billion (7.4% growth).
- Innovative Medicine segment sales grew 7.7% operationally; MedTech segment sales grew 2.5% operationally.
- Acquisition of Firefly Bio, Inc. and strategic collaboration with Sail Biomedicines announced.
- FDA approved IMAAVY for warm autoimmune hemolytic anemia (wAIHA).
- OTTAVA™ Robotic Surgical System received FDA market authorization in the U.S.
- Proposed resolution of Ovarian Talc Litigation announced.
Price Impact
More from JNJ